07:31 AM EST, 11/02/2026 (MT Newswires) -- BofA Global Research views Novartis' (NOVN.SW) upcoming late-stage data readout for investigational anticoagulant abelacimab in the prevention of stroke and systemic embolism in atrial fibrillation patients as the key catalyst for the Swiss drugmaker in 2027. "Abelacimab [Factor XI] PIII in SPAF (in patients at high risk of bleeding deemed unsuitable for anti-coagulation) is due 1H27E and could be NVS' most important 27E data catalyst," analysts said in a Monday note. "We think PIII is highly likely to hit based on PII data and PIII placebo comparator. Key is therefore: (1) Magnitude of efficacy benefit, with our KOL expecting a>50% relative risk-reduction for abelacimab vs placebo based on prior AF studies; and (2) Major bleed rates, with doc expecting around c5%for placebo arm (higher than prior studies) with 1-2% delta higher for abelacimab deemed acceptable." Peak sales for abelacimab are projected to be in the $2 billion to $5 billion range, with analysts noting that the atrial fibrillation market is estimated at more than $20 billion. The research firm maintained the stock's buy rating, with a price objective of 150 francs, against this backdrop, alongside "solid" sales growth expectations for 2027 and other major catalysts including the data readout for multiple sclerosis drug Kesimpta in a phase 3 study evaluating a once-every-two-months maintenance dose.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.